Adverse Events With Pertuzumab and Trastuzumab: Evolution During Treatment With and Without Docetaxel in CLEOPATRA

摘要

Trastuzumab and pertuzumab both bind to HER2 but with distinct binding sites and complementary mechanisms of action. Hence, combining these 2 monoclonal antibodies could induce a more comprehensive blockade of HER2 signaling. The antibody combination has shown greater efficacy relative to trastuzumab alone, both in the HER2-positive neoadjuvant setting and in metastatic breast cancer, and is well tolerated in the absence of chemotherapy.1'3 Jose Baselga, MD, PhD, presented safety data comprising non-cardiac adverse events during and after treatment with docetaxel from the randomized, placebo-controlled, phase III CLEOPATRA trial.4 The trial randomized 406 patients to receive trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) plus docetaxel (75 mg/m2, escalating to 100 mg/m2 if tolerated) and 402 patients to receive the same treatment plus pertuzumab (840 mg loading dose followed by 420 mg) administered intravenously every 3 weeks.5 At least 6 cycles of docetaxel were recommended.